Edgewise Therapeutics Inc (EWTX)
31.44
-1.43
(-4.35%)
USD |
NASDAQ |
Nov 15, 16:00
31.44
0.00 (0.00%)
After-Hours: 20:00
Edgewise Therapeutics Research and Development Expense (TTM): 118.28M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 118.28M |
| June 30, 2024 | 109.84M |
| March 31, 2024 | 98.72M |
| December 31, 2023 | 90.90M |
| September 30, 2023 | 79.83M |
| June 30, 2023 | 69.94M |
| March 31, 2023 | 62.78M |
| December 31, 2022 | 54.03M |
| Date | Value |
|---|---|
| September 30, 2022 | 46.51M |
| June 30, 2022 | 42.49M |
| March 31, 2022 | 37.95M |
| December 31, 2021 | 32.19M |
| September 30, 2021 | 28.24M |
| June 30, 2021 | 21.60M |
| March 31, 2021 | 17.38M |
| December 31, 2020 | 14.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
14.98M
Minimum
Dec 2020
118.28M
Maximum
Sep 2024
57.86M
Average
50.27M
Median
Research and Development Expense (TTM) Benchmarks
| Catalyst Pharmaceuticals Inc | 10.82M |
| Cytokinetics Inc | -- |
| Vanda Pharmaceuticals Inc | 78.93M |
| Vertex Pharmaceuticals Inc | 3.456B |
| Sarepta Therapeutics Inc | 800.09M |